MISSISSAUGA, ON, July 5, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that the Company's partner, Moberg Pharma AB, ("Moberg Pharma") has obtained European Union approval for MOB-015 (nail fungus treatment) as a result of demonstrating superior levels of mycological cure (76% vs. 42% for comparators) and a significantly better complete cure rate.
Read more at newswire.caProvided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.